GMED — Globus Medical, Inc.

Summary of GMED Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $759.9 million, up 27% year-over-year (25.5% on a constant currency basis).
• Base Business Revenue: $677.2 million, growing 13.2% year-over-year.
• Non-GAAP EPS: $1.12, a 64.7% increase from the prior year.
• GAAP Net Income: $124.3 million, with GAAP EPS of $0.90.
• Adjusted Gross Profit Margin: 69.2%, up from 67.3% in the prior year.
• Cash and Marketable Securities: $799.3 million as of March 31, 2026.
• Nevro Revenue: $82.7 million, down 17.1% sequentially from Q4 2025.

2. Strategic Updates and Business Highlights

• U.S. Spine Business: Grew 10% for the third consecutive quarter, contributing to overall strength in the domestic market.
• International Spine Business: Increased by 16.4% as reported, attributed to improved supply chain conditions.
• Enabling Technologies: Revenue of $26.9 million, growing 21% year-over-year, with a shift towards more flexible leasing and rental models.
• Product Launches: Received FDA 510(k) clearance for patient-specific Scripps spacer and rod systems, enhancing the product portfolio.
• Trauma Business: Posted a 34% increase, driven by strong demand for the Anthem elbow plating system and the PRECICE limb lengthening portfolio.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Reaffirmed at $3.18 billion to $3.22 billion, indicating growth of 8.2% to 9.6% over 2025.
• Non-GAAP EPS Guidance: Increased to $4.70 to $4.80, up from the previous range of $4.40 to $4.50, reflecting improved margin expectations.
• Long-term Gross Margin Target: Aiming for mid-70s adjusted gross margin, with expectations for gradual improvement throughout the year.

4. Bad News, Challenges, or Points of Concern

• Nevro Business: Experienced a revenue decline due to structural changes in sales and marketing, anticipated to continue impacting results in the near term.
• Competitive Pressures: Increased competition in the robotics space, leading to elongated deal closure times.
• Market Dynamics: The company noted potential lumpiness in revenue from the Nevro business and a cautious approach to revenue guidance, reflecting uncertainties in the enabling technologies segment.

5. Notable Q&A Insights

• Revenue Guidance: Management expressed confidence in their revenue guidance despite acknowledging potential headwinds from Nevro and changes in enabling tech sales strategies.
• Market Share Gains: Most growth in U.S. Spine attributed to market share gains rather than overall market growth, which is estimated at 3% to 3.5%.
• Competitive Landscape: The company remains well-positioned against competitors, particularly Medtronic, with a strong pipeline and continued focus on innovative product offerings.
• Operational Focus: Emphasis on maintaining operational discipline and leveraging manufacturing efficiencies to achieve long-term profitability goals.

Overall, GMED reported a strong start to 2026, with significant revenue growth and margin expansion, while navigating challenges related to the integration of Nevro and competitive pressures in the market.